Comparison · NCT00446641-3bfb13ca
Cilostazol vs Placebo: Aspirin Resistance (ARU ≥ 550)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Cilostazol vs Placebo: Aspirin Resistance (ARU ≥ 550). Trial comparisons, record NCT00446641-3bfb13ca. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00446641-3bfb13ca
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0833 | 0.0445 | 0.151 | wilson | |
| Risk in group 2 | 0.101 | 0.0573 | 0.172 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0176 | -0.0984 | 0.0628 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.826 | 0.357 | 1.91 | log | |
| Odds ratio, group 1 over group 2 | 0.81 | 0.321 | 2.04 | log | |
| Number needed to treat, for one fewer participant with the outcome on Cilostazol than on Placebo | 56.9 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Cilostazol | Cilostazol 100mg twice per day | 9 | 108 | OG000 |
| Group 2 | Placebo | matching placebo to cilostazol | 11 | 109 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Aspirin Resistance (ARU ≥ 550)
- Description
- The number of patients with aspirin reaction units (ARUs) values ≥ 550 on the Ultra Rapid Platelet Function Assay-ASA among the recruited patients
- Time frame
- 4 weeks after treatment
- Population
Source ClinicalTrials.gov
Trial
- Title
- Overcome Biochemical Aspirin Resistance Through Cilostazol Combination
- NCT number
- NCT00446641
- Phases
- PHASE4
- Conditions
- Cerebral Infarction
- Interventions
- Cilostazol, placebo
- Lead sponsor
- Asan Medical Center
- Results first posted
- 2010-01-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00446641?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00446641-3bfb13ca